Matthew A Lunning

Apr 27, 2024 | targetedonc.com | Matthew A Lunning

Matthew Lunning, DO, FACP, associate professor in the division of hematology/oncology, assistant vice chancellor of clinical research, and associate vice chair of research in the department of internal medicine at the University of Nebraska Medical Center, discusses the use of chimeric antigen receptor (CAR) T-cell therapies in the second-line setting for patients with B-cell lymphoma.

Apr 18, 2024 | onclive.com | Matthew A Lunning |Sarah Rutherford

April 18, 2024Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age. The Blood Club, hosted by Matthew Lunning, DO, FACP, is a podcast that seeks to translate the latest hematologic oncology research findings into practical clinical implications for the treatment of patients with hematologic malignancies.

Mar 18, 2024 | onclive.com | Alex Herrera |Álex Herrera |Matthew A Lunning

March 18, 2024Dr Lunning sits down with Alex Herrera, MD, to discuss the frontline management of Hodgkin lymphoma, including the SWOG 1826 trial. The Blood Club, hosted by Matthew Lunning, DO, FACP, is a podcast that seeks to translate the latest hematologic oncology research findings into practical clinical implications for the treatment of patients with hematologic malignancies.

Feb 20, 2024 | onclive.com | Grzegorz S Nowakowski |Jennifer Crombie |Matthew A Lunning |Peter Martin |Laurie H. Sehn |Bijal Shah

Future Directions and Unmet Needs in Relapsed/Refractory MCLA panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

Feb 13, 2024 | onclive.com | Grzegorz S Nowakowski |Jennifer Crombie |Matthew A Lunning |Peter Martin |Laurie H. Sehn |Bijal Shah

Sequencing Therapies in the Third-Line and Beyond Setting for MCLA panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.